

Taumedis is a medical technology start-up specializing in intraoperative imaging solutions that enhance surgical outcomes by streamlining procedures and lowering surgical complexity, while reducing acquisition costs and minimizing OR downtime. Our solutions deliver high-quality images that are seamlessly integrated into the surgical theatre.

Market Opportunity

The intraoperative imaging market (SAM) was valued at \$2.8B in 2022 and is projected to reach \$4.61B by 2032, growing at a CAGR of 5.7% (1). Our primary focus is the \$780M/yr (SOM) intraoperative MRI neurosurgical sector, with an initial emphasis on top-tier academic hospitals performing advanced surgeries.

Clinical Problem / Unmet Need

Neurosurgical procedures associated with illnesses like brain cancer and neurovascular disease require intraoperative imaging. During these procedures, patients can either be moved to the imaging equipment or the equipment can be moved to the patient. Moving patients increases complexity, time, cost, infection and outcomes risks. Available intraoperative mobile imaging requires large capital expenditures >\$8M, 6 months+ renovation time, O.R. down time and major facility renovations. Providing a top quality intraoperative image solution, with minimal OR down time and facility renovations at significantly lower costs are major unmet needs that Taumedis solutions will resolve.


Product & Technology Development



iMRI: Next-generation ground-moving intraoperative MRI (iMRI) designed for modern surgical theaters, minimizing construction and OR downtime requirements and optimizing operational efficiency. FDA approval Q1 2026, CE Mark Q3 2026, Aus/NZ clearance expected Q4 2026.



iUS: Patent-pending probe-less intraoperative ultrasound (iUS) that adheres to the patient's skin, offering real-time 3D imaging. FDA approval expected 2028.



iPET: A compact, portable intraoperative PET (iPET) system that transforms traditional PET imaging for surgical environments. FDA approval expected Q3 2027.

Competitive Advantage

Unlike traditional intraoperative imaging systems requiring patient transport, Taumedis' solutions integrate seamlessly into the surgical workflow. Taumedis delivers solutions that will increase hospital adoption and take a leadership position over competition through:

- Lower acquisition costs – a projected 30%+ reduction
- Reduced OR downtime – completing OR turnover in roughly 3 months
- Smaller OR footprint – designed to accommodate most modern ORs

Provisionals and IP on iMRI, iPET, and iUS.

Business Model & Growth

Taumedis generates revenue through medical device sales, value-added applications, and services. Existing CPT codes support reimbursement, first revenues anticipated in Q2 2026 from iMRI sale to leading hospital based in USA.

(1) Source: <https://www.fortunebusinessinsights.com/intraoperative-imaging-market-107679>.

Industry

Healthcare, Medical Devices, Imaging

Products

iMRI, iPET, iUS

Leadership

Seasoned medical device professionals with proven expertise in developing and commercializing imaging-based solutions, consistently delivering strong returns for investors.

- Henry Floreal, MBA - CEO, Chairman
- Michael Zhang, PhD - CSO
- Michael Lang, PhD - CTO
- Michael Schulder, MD - Clinical Advisor
- Sean Gallimore, MBA - Director

Financing

\$700K USD pre-seed to file **iMRI 510(k)** and develop iPET proof-of-concept, closing Q2 2025.

Use of pre-seed funds:

- Establish QMS and company procedures
- Submit 510k package for North American made ground-moving iMRI system
- Proof of concept for iPET
- Grow commercial team

\$5M USD seed funding for **510(k) clearance of 2nd-gen iMRI system**, iPET 510(k) filing, iUS prototype, and **further** market expansion, closing Q1 2026.

Use of seed funds:

- 2nd gen ground-moving iMRI system
- Additional geographic expansion
- Winnipeg based imaging center / lab
- iPET market introduction
- iUS prototype

Contact

CEO Henry Floreal

+1-431 -554-3164

hfloreal@taumedis.com